Tracking a blood Thinner's performance against dangerous drug reaction
NCT ID NCT00861692
Summary
This study aimed to collect real-world information on how well the drug argatroban works for treating a serious condition called heparin-induced thrombocytopenia (HIT) Type II. HIT is a dangerous reaction to the blood thinner heparin that causes low platelets and a high risk of blood clots. The study followed 20 adult patients with suspected or confirmed HIT to monitor outcomes like death, new blood clots, bleeding, and recovery of platelet counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Saint-Etienne, France
Conditions
Explore the condition pages connected to this study.